Literature DB >> 11839635

Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease.

Kumi Yasukawa1, Masaru Terai, Stanford T Shulman, Tetsuya Toyozaki, Shigehiro Yajima, Yoichi Kohno, Anne H Rowley.   

Abstract

BACKGROUND: Increased vascular permeability is an important event during the initial process of Kawasaki disease (KD). One potential responsible candidate for the induction of vascular hyperpermeability is vascular endothelial growth factor (VEGF). METHODS AND
RESULTS: We investigated the expression of VEGF and its receptors (flt-1, KDR) in acute KD tissues at 7 days to 5 weeks of illness. Neuropilin-1, which enhances the binding of VEGF(165) to KDR, was also studied. Abundant expression of VEGF and flt-1 was documented immunohistochemically in many organs from acute KD, including heart and lung. VEGF and flt-1 were colocalized in all vessels that showed edema. These molecules resided in endothelium and vascular media and also in migrating smooth muscle cells in neointima and infiltrating macrophages. Compared with controls, coronary vessels of acute KD had upregulation of VEGF and flt-1 but not KDR or neuropilin-1. KDR was expressed by vessels at 7 days of illness but not later in the illness. Plasma proteins were more extensively bound to the extracellular matrix in coronary vessels in acute KD than controls. Furthermore, elevation of serum VEGF levels was correlated with low serum albumin in acute KD (n=220, r=-0.53, P<0.001).
CONCLUSIONS: These findings suggest that VEGF and flt-1 are upregulated in blood vessels in many organs of acute KD. Expression of KDR was limited to the early stage of acute KD. The roles of VEGF in acute KD may involve promotion of vascular permeability and macrophage activation. Low serum albumin may indicate overproduction of VEGF in acute KD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839635     DOI: 10.1161/hc0602.103396

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

1.  Angiogenesis in fatal acute Kawasaki disease coronary artery and myocardium.

Authors:  A F Freeman; S E Crawford; M L Cornwall; F L Garcia; S T Shulman; A H Rowley
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

2.  Assessment of risk factors for Korean children with Kawasaki disease.

Authors:  Jae-Jung Kim; Young Mi Hong; Sin Weon Yun; Myung Ki Han; Kyung-Yil Lee; Min Seob Song; Hyoung-Doo Lee; Dong Soo Kim; Sejung Sohn; Kee-Soo Ha; Soo-Jong Hong; Kwi-Joo Kim; In-Sook Park; Gi Young Jang; Jong-Keuk Lee
Journal:  Pediatr Cardiol       Date:  2011-11-22       Impact factor: 1.655

3.  Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease.

Authors:  S Takeshita; Y Kawamura; H Takabayashi; N Yoshida; S Nonoyama
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

4.  Lack of association of the vascular endothelial growth factor gene polymorphisms with Kawasaki disease in Taiwanese children.

Authors:  Fu-Yuan Huang; Tzu-Yang Chang; Ming-Ren Chen; Hung-Chang Lee; Hsin Chi; Nan-Chang Chiu; Chyong-Hsin Hsu; Shuan-Pei Lin; Hsin-An Kao; Wei-Fang Chen; Hui-Wen Chan; Hsin-Fu Liu; Chen-Chung Chu; Marie Lin; Yann-Jinn Lee
Journal:  J Clin Immunol       Date:  2008-02-23       Impact factor: 8.317

5.  Hepatocyte growth factor inhibits VEGF-forkhead-dependent gene expression in endothelial cells.

Authors:  Md Ruhul Abid; Robert J Nadeau; Katherine C Spokes; Takashi Minami; Dan Li; Shou-Ching Shih; William C Aird
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-11       Impact factor: 8.311

6.  Water retention in the acute phase of Kawasaki disease: relationship between oedema and the development of coronary arterial lesions.

Authors:  Hiroyuki Suzuki; Takashi Takeuchi; Takaomi Minami; Shoichi Shibuta; Shigeru Uemura; Norishige Yoshikawa
Journal:  Eur J Pediatr       Date:  2003-10-15       Impact factor: 3.183

7.  The CCR5 (-2135C/T) polymorphism may be associated with the development of Kawasaki disease in Korean children.

Authors:  Won Kyoung Jhang; Mi-Jin Kang; Hyun-Seung Jin; Jinho Yu; Byoung-ju Kim; Bong Seong Kim; Jong-Keuk Lee; Eul-Ju Seo; Han-Wook Yoo; In Sook Park; Young Mi Hong; Soo-Jong Hong
Journal:  J Clin Immunol       Date:  2008-07-15       Impact factor: 8.317

8.  Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease.

Authors:  Toshiaki Jibiki; Masaru Terai; Tomomichi Kurosaki; Hiromichi Nakajima; Kazuhiro Suzuki; Hiroaki Inomata; Itaru Terashima; Takafumi Honda; Kumi Yasukawa; Hiromichi Hamada; Yoichi Kohno
Journal:  Eur J Pediatr       Date:  2004-02-13       Impact factor: 3.183

9.  Genetic polymorphism of SMAD5 is associated with Kawasaki disease.

Authors:  Ja Hyang Cho; Mi Young Han; Sung Ho Cha; Joo Ho Jung; Kyung Lim Yoon
Journal:  Pediatr Cardiol       Date:  2013-10-26       Impact factor: 1.655

10.  The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies.

Authors:  E Grunebaum; M Blank; S Cohen; A Afek; J Kopolovic; P L Meroni; P Youinou; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.